Gambro

Gambro. It was a pioneering Swedish medical technology company, founded in 1964 by industrialist Holger Crafoord, that became a global leader in the development and manufacturing of products for kidney dialysis and blood purification. The company played a seminal role in transforming renal replacement therapy from an experimental procedure into a widespread, life-sustaining treatment for end-stage renal disease. Its innovations in hollow fiber dialyzers and hemodialysis machines were instrumental in establishing the modern clinical practice of dialysis and were used to treat millions of patients worldwide before the company was fully integrated into Baxter International in 2013.

History

The company's origins are deeply tied to the collaboration between Holger Crafoord and pioneering physician Nils Alwall at Lund University, who had developed an early artificial kidney device. Following Alwall's work, Crafoord established Gambro in 1964 to commercialize these technologies, with the name derived from the Swedish words for "gambro" (brother-in-law), reflecting a family connection. A major breakthrough came in 1967 with the launch of the Gambro Lundia Minor, one of the first commercially produced hemodialysis machines, which helped enable the broader adoption of chronic dialysis treatment. Throughout the 1970s and 1980s, under leaders like Gösta Wictorin, the company expanded internationally, establishing subsidiaries across Europe, North America, and Asia, and solidified its position through continuous innovation in dialyzer membrane technology. The 1990s saw strategic shifts, including a brief merger with the Swedish conglomerate Investor AB and the subsequent spin-off of its hospital supplies division, which later became Getinge Group.

Products and services

Gambro's core product portfolio centered on extracorporeal blood treatment systems for acute kidney injury and chronic kidney disease. Its most significant products included a wide range of hollow fiber dialyzers, such as those using cuprophane and later more biocompatible synthetic membranes like polyamide and polyethersulfone, which were critical components for blood filtration. The company manufactured several generations of hemodialysis machines, including the AK series and the Phoenix system, which incorporated advanced features for ultrafiltration control and patient monitoring. For peritoneal dialysis, Gambro produced PD solutions and APD systems like the HomeChoice cycler. It also developed specialized equipment for therapeutic apheresis and continuous renal replacement therapy (CRRT) used in intensive care units, such as the Prisma system.

Corporate affairs

For much of its history, Gambro was headquartered in Lund, Sweden, with major research and manufacturing facilities also located in Hechingen, Germany, and Lakewood, Colorado, in the United States. The company was publicly listed on the Stockholm Stock Exchange and experienced significant ownership changes; from 2006 to 2013, it was majority-owned by the private equity firms EQT Partners and Investor AB. Its operational structure was organized into global business units for Dialysis Products, Renal Care Services, and Hospital Products. Gambro maintained a strong focus on clinical education and technical support, running extensive training programs for nephrology staff worldwide through its Gambro Academy initiative to ensure the safe and effective use of its technologies.

Clinical impact

Gambro's technological contributions had a profound effect on the field of nephrology and patient outcomes. The company's development of efficient, reliable, and safer dialyzers and machines was fundamental to the establishment and growth of outpatient dialysis centers, enabling the shift from hospital-based to more accessible community-based care. Its work on improving membrane biocompatibility helped reduce inflammatory responses and complications during dialysis sessions. Gambro's systems for CRRT provided a vital treatment option for critically ill patients in ICUs with multiple organ dysfunction syndrome. The widespread adoption of its technologies supported the expansion of dialysis programs globally, significantly extending the lives of patients with ESRD and influencing clinical guidelines set by bodies like the National Kidney Foundation.

Acquisitions and partnerships

Gambro's growth was significantly driven by a series of strategic acquisitions and alliances. In 1989, it acquired the dialysis business of Travenol Laboratories, which later became part of Baxter International, marking a major expansion in the U.S. market. In 1998, Gambro purchased the Water Treatment division of Cobe Laboratories, strengthening its offering for dialysis water purification systems. A pivotal merger occurred in 2004 with the renal care division of B. Braun Melsungen, creating one of the world's largest dialysis providers, though this venture was later dissolved. The company also formed numerous research collaborations with academic institutions, including Lund University and the University of Michigan, and technology partnerships with firms like Fresenius Medical Care. Gambro's corporate history concluded when it was acquired in its entirety by Baxter International in a transaction finalized in 2013.

Category:Medical equipment companies of Sweden Category:Companies established in 1964 Category:Companies disestablished in 2013